B3P Stock Overview
An investment trust, primarily invests in interest-bearing debt assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BioPharma Credit PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$0.85 |
| 52 Week Low | US$0.74 |
| Beta | 0.24 |
| 11 Month Change | 1.28% |
| 3 Month Change | -1.86% |
| 1 Year Change | 5.33% |
| 33 Year Change | -1.86% |
| 5 Year Change | n/a |
| Change since IPO | -4.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| B3P | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -0.2% | -1.5% |
| 1Y | 5.3% | 28.2% | 7.9% |
Return vs Industry: B3P underperformed the German Capital Markets industry which returned 27.6% over the past year.
Return vs Market: B3P underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| B3P volatility | |
|---|---|
| B3P Average Weekly Movement | 5.6% |
| Capital Markets Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B3P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: B3P's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.bpcruk.com |
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in London, the United Kingdom.
BioPharma Credit PLC Fundamentals Summary
| B3P fundamental statistics | |
|---|---|
| Market cap | €976.66m |
| Earnings (TTM) | €103.88m |
| Revenue (TTM) | €129.53m |
9.4x
P/E Ratio7.5x
P/S RatioIs B3P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B3P income statement (TTM) | |
|---|---|
| Revenue | US$136.37m |
| Cost of Revenue | US$0 |
| Gross Profit | US$136.37m |
| Other Expenses | US$27.01m |
| Earnings | US$109.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.092 |
| Gross Margin | 100.00% |
| Net Profit Margin | 80.20% |
| Debt/Equity Ratio | 0% |
How did B3P perform over the long term?
See historical performance and comparison